Please provide your email address to receive an email when new articles are posted on . Researchers observed better OS in patients with NSCLC who experienced immune-related adverse events. The ...
ICIs, representing a revolutionary breakthrough in cancer immunotherapy, restore T-cell antitumor activity by targeting and blocking inhibitory immune molecules, thereby significantly extending the ...
Black patients have longer time to treatment discontinuation, similar time to next treatment, slightly improved overall survival than White patients. (HealthDay News) — Black patients have similar ...
These treatments are "revving up the immune system," said Bryan J. Schneider, MD, of the University of Michigan in Ann Arbor, who co-chaired the group that updated the American Society of Clinical ...
Patients who are prescribed antibiotics during immune checkpoint blockade therapy for solid tumors face a heightened risk for ...
WASHINGTON, DC — Cutaneous immune-related adverse events (cirAEs) in oncology patients receiving immune checkpoint inhibitors (ICIs) should be treated in as targeted a fashion as possible and with ...
Adding an immune checkpoint inhibitor to standard Bacillus Calmette-Guérin (BCG) therapy for non–muscle invasive bladder cancer (NMIBC) might reduce recurrences in a small fraction of patients, but ...
Our immune system guards against cancer development by constantly surveilling the body and eliminating unhealthy cells. Immune cells are highly suspicious of other cells. While this leads to a swift ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback